genOway | ULTIMATE PREDICTABILITY

genO-hCD4 (scan or click)

HUMANIZED genO-hCD4 MOUSE MODEL

The humanized genO-hCD4 mouse model allows *in vivo* efficacy and safety assessment of anti-human CD4 compounds.

APPLICATIONS

- Assess the **efficacy** of CD4-targeting compounds
- Gain insights into the mechanism of action (MOA) of diverse constructs and their potential therapeutic benefits
- Analyze the biodistribution of hCD4-targeting constructs and follow the dynamics of CD4+ T cells by live imaging



MODEL FEATURES

- Physiological regulation and expression pattern of hCD4
- Unaltered immune cell distribution, and T helper cell activity
- Fully functional mouse immune system
- Lack of expression of the murine target gene, thus avoiding cross-reactivity

ORDERS, DELIVERY & CARE

- Orders are made directly with genOway; breeding, housing and delivery are outsourced
- Breeding facilities in the US and Europe through our trusted partners:

TACONIC BIOSCIENCES charles river


- Quick, compliant, and reliable door-to-door delivery worldwide at your facility or at the CRO of your choice
- Models with certified **SOPF** health status from **AAALAC-accredited** and **PHS-assured** professional breeders

genOway | ULTIMATE PREDICTABILITY


genO-hCD4 (scan or click)

SELECTED VALIDATION DATA

More data available on our website or upon request




Human CD4 replaces murine CD4. Homozygous genO-hCD4 humanized mice display human-CD4 expression in PBMC. No murine CD4 expression is observed




The distribution of CD4+ T cells in response to ICI therapy can be followed in genO-hCD4 mice using radiotracers

EBERHARD KARLS UNIVERSITÄT TÜBINGEN



Unaltered immune cell distribution. Homozygous genO-hCD4 humanized mice display same frequencies of B cells, NK cells and T cells in spleen



Conserved cytokine expression profile. Homozygous genO-hCD4 humanized mice display similar cytokine expression after ConA stimulation

KEY PUBLICATIONS

Theranostics

In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4+ cells and response prediction to cancer immunotherapy
Pezzana et al., 2024 - Theranostics

ScienceAdvances

PET-based immunomapping of intratumoral CD4+ cells to monitor acquired resistance to checkpoint inhibitors
Pezzana et al., 2025 - Sci Adv

frontiers in Immunology

Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells
Traenkle et al., 2022 - Front Immunol

RELATED MODELS

genO-hIgE/hFcεR1 | **genO-hTNF-α**

For more information

Visit the genO-hCD4 page

For further inquiries

Contact Us